Chalcogen And -c(=x)-, Wherein X Is Chalcogen, Bonded Directly To Ring Carbons Of The Bicyclo Ring System (e.g., 4-oxo-naphthyridine -3-carboxylic Acid, Etc.) Patents (Class 546/123)
  • Patent number: 6723332
    Abstract: Disclosed are compounds of the formula: wherein: A, B, C, E, F, and G are substituents as defined herein, which compounds bind to the benzodiazepine site of GABAA receptors and are therefore useful in treatment of central nervous system (CNS) diseases.
    Type: Grant
    Filed: May 24, 2001
    Date of Patent: April 20, 2004
    Assignee: Neurogen Corporation
    Inventors: Guolin Cai, Pamela A. Albaugh, Kenneth Shaw
  • Publication number: 20040063754
    Abstract: 3-(1-Aminocycloalkyl)pyrrolidinyl-substituted-6-dehalodeno(hydrogen-substituted)quinolon carboxylic acid derivatives having specific substitunets as represented by the following formula (I), its salts, and hydrates thereof exhibit a broad and potent antibacterial activity on gram-negative and gram-positive bacteria, in particular, resistant bacteria typified by gram-positive cocci, including MRSA, PRSP and VRE. Thus these compounds are usable as drugs.
    Type: Application
    Filed: May 19, 2003
    Publication date: April 1, 2004
    Inventors: Hisashi Takahashi, Rie Miyauchi, Masao Itoh, Makoto Takemura, Isao Hayakawa
  • Patent number: 6699989
    Abstract: Disclosed are guanidine and biguanidine derivatives which have anti-viral and anti-bacterial activity. Also disclosed are pharmaceutical compositions containing such compounds as an active ingredient, and anti-viral and anti-bacterial methods utilizing such compounds.
    Type: Grant
    Filed: August 28, 2000
    Date of Patent: March 2, 2004
    Inventor: B. Vithal Shetty
  • Patent number: 6693101
    Abstract: The present invention relates to novel alkanoic acid derivatives thereof, their synthesis, and their use as &agr;v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3 and/or &agr;v&bgr;5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: February 17, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Ben C. Askew, Michael J. Breslin, Mark E. Duggan, John H. Hutchinson, Robert S. Meissner, James J. Perkins, Thomas G. Steele, Michael A. Patane
  • Publication number: 20040029882
    Abstract: Compounds of the following formula: 1
    Type: Application
    Filed: July 30, 2003
    Publication date: February 12, 2004
    Applicant: The Procter & Gamble Co.
    Inventors: Benoit Ledoussal, Xiufeng Eric Hu, Ji-In Kim Almstead, Jeffrey Lyle Gray
  • Publication number: 20040019214
    Abstract: An ester or amide derivative represented by the general formula (I) or a pharmaceutically acceptable salt thereof. Particularly, an ester or amide derivative of 4-oxo-1,4-dihydroqunoline-2-carboxylic acid represented by the general formula (I′) or (I″), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 28, 2003
    Publication date: January 29, 2004
    Inventors: Jun-ichi Kazami, Masato Watanabe, Takuya Hirata
  • Patent number: 6677351
    Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt thereof, are phosphodiesterrase 4 inhibitors useful in the treatment of asthma and inflammation.
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: January 13, 2004
    Assignee: Merck Frosst Canada & Co.
    Inventors: Chun Li, Mario Girard, Pierre Hamel, Sebastien Laliberte, Richard Friesen, Yves Girard, Daniel Guay
  • Patent number: 6677352
    Abstract: The invention relates generally to naphthyridine derivatives of the formula wherein one of U, X, Y and Z is nitrogen and the others are C—R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,6-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for the treatment of diabetes and related disorders.
    Type: Grant
    Filed: September 23, 2002
    Date of Patent: January 13, 2004
    Inventors: Yamin Wang, William H. Bullock, Libing Chen
  • Publication number: 20030232818
    Abstract: Antibacterials having formula (I) 1
    Type: Application
    Filed: March 12, 2003
    Publication date: December 18, 2003
    Inventors: David Anderson, Bruce Beutel, Todd D. Bosse, Richard Clark, Curt Cooper, Peter Dandliker, Caroline David, Yu-Gui Gu, Todd Matthew Hansen, Mira Hinman, Douglas Kalvin, Daniel P. Larson, Linda Lynch, Zhenkun Ma, Christopher Motter, Fabio Palazzo, Teresa Rosenberg, Tamara Rehm, William Sanders, Michael Tufano, Rolf Wagner, Moshe Weitzberg, Hong Yong, Tianyuan Zhang
  • Patent number: 6646124
    Abstract: The present invention encompasses structures of the Formula or the pharmaceutically acceptable non-toxic salts thereof wherein: X is hydrogen, halogen, (un)substituted alkyl, (un)substituted alkoxy or amino; and Y is (un)substituted alkyl, aryl, or heteroaryl, which compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors. These compounds are useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, and overdose with benzodiazepine drugs and for enhancement of alertness.
    Type: Grant
    Filed: April 2, 2002
    Date of Patent: November 11, 2003
    Assignee: Neurogen Corporation
    Inventors: Pamela A. Albaugh, Robert W. DeSimone, Gang Liu
  • Publication number: 20030171584
    Abstract: The present invention provides compounds of the Formula I and II: 1
    Type: Application
    Filed: February 11, 2002
    Publication date: September 11, 2003
    Inventors: Jian Jeffrey Chen, James Patrick Dunn, David Michael Goldstein, Christoph Martin Stahl
  • Patent number: 6605611
    Abstract: Nucleoside analogues or base analogues having structure (I), where X=O or NH or S, Y=N or CHR6 or CR6, W=N or NR6 or CHR6 or CR6 or S, n=1 or 2; each R6 is independently H or O or alkyl or alkenyl or alkoxy or aryl or a reporter moiety; where necessary (i.e. when Y and/or W is N or CR6 where R6 is not O) a double bond is present between Y and W or W and W, and Q is H or a sugar or a sugar analogue or a nucleic acid backbone or backbone analogue.
    Type: Grant
    Filed: September 3, 2002
    Date of Patent: August 12, 2003
    Assignee: Nycomed Amersham PLC
    Inventors: Adrian Christopher Simmonds, Alan Hamilton, Clifford Smith, David Loakes, Daniel Brown, Fergal Hill, Shiv Kumar, Satyam Nampalli, Mark McDougall
  • Patent number: 6603005
    Abstract: Heterocyclylalkylpiperidine derivatives of general formula (I) in their enantiomeric or diastereoisomeric forms or mixtures of these forms, and/or, where appropriate, in their syn or anti form or a mixture thereof, as well as any salt thereof.
    Type: Grant
    Filed: November 14, 2001
    Date of Patent: August 5, 2003
    Assignee: Aventis Pharma S.A.
    Inventors: Eric Baque, Jean-Christophe Carry, Youssef El-Ahmad, Michel Evers, Philippe Hubert, Jean-Luc Malleron, Serge Mignani, Guy Pantel, Michel Tabart, Fabrice Viviani
  • Publication number: 20030130302
    Abstract: Quinolone carboxylic acid derivatives of formula (I) and pharmaceutically acceptable salts thereof have potent antibacterial activity: 1
    Type: Application
    Filed: December 27, 2002
    Publication date: July 10, 2003
    Inventors: Tae-Ho Park, Sang-Ho Lee, Cheol Han
  • Publication number: 20030119848
    Abstract: 1
    Type: Application
    Filed: August 7, 2002
    Publication date: June 26, 2003
    Inventors: Makoto Takemura, Hisashi Takahashi, Katsuhiro Kawakami, Kenji Namba, Mayumi Tanaka, Rie Miyauchi
  • Publication number: 20030114478
    Abstract: Compounds represented by Formula (I): 1
    Type: Application
    Filed: August 23, 2002
    Publication date: June 19, 2003
    Inventors: Daniel Guay, Mario Girard, Pierre Hamel, Sebastien Laliberte, Richard Friesen
  • Publication number: 20030113336
    Abstract: The present invention describes novel compounds of the formula:
    Type: Application
    Filed: October 26, 2002
    Publication date: June 19, 2003
    Inventors: Thomas D. Harris, John A. Barrett, Alan P. Carpenter,, Milind Rajopadhye
  • Patent number: 6573260
    Abstract: This invention provides a quinolone derivative which exerts strong antibacterial action upon various bacteria and has high safety, and it relates to a compound having a structure of formula (I), its salts and hydrates thereof: {R1 and R2: hydrogen, alkyl; n: 1 to 4; Q: following structure (Ia): [R3: alkyl, alkenyl, halogenoalkyl, cyclic alkyl, aryl, heteroaryl, alkoxyl, alkylamino; R4: hydrogen, alkylthio; R5: hydrogen, amino, hydroxyl, thiol, halogenomethyl, alkyl, alkenyl, alkynyl, alkoxyl; X1: halogen, hydrogen, A1: nitrogen, structure of formula (II): (X2: hydrogen, amino, halogen, cyano, halogenomethyl, halogenomethyl, alkyl, alkenyl, alkynyl, alkoxyl; R4 and R3 or X2 and R3 may together form a cyclic structure; Y: hydrogen, various ester forming groups]}.
    Type: Grant
    Filed: May 24, 2001
    Date of Patent: June 3, 2003
    Assignee: Daiichi Pharmaceutical Co., Ltd.
    Inventors: Makoto Takemura, Hisashi Takahashi, Rie Miyauchi, Toshiyuki Takeda, Isao Hayakawa
  • Publication number: 20030096812
    Abstract: This invention relates to new generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, to their optical isomers, diastereomers or enantiomers, as well as pharmaceutically acceptable salts, hydrates, prodrugs, polymorphs and pseudopolymorphs thereof, to their preparation, to their compositions and to their use.
    Type: Application
    Filed: April 23, 2002
    Publication date: May 22, 2003
    Applicant: WOCKHARDT LIMITED
    Inventors: Noel John De Souza, Mahesh Vithalbhai Patel, Prasad Keshav Deshpande, Shiv Kumar Agarwal, Shrikant V. Gupte, Dilip J. Upadhyay, Satish B. Bhawsar, Rupinder K. Beri, Kandepu Sreenivas, Sheela Chandrasekharan Nair, Milind Chintaman Shukla, Yati Chugh, Nitin Shetty, Ravindra D. Yeole, M. Madhav Reddy
  • Publication number: 20030096829
    Abstract: Compounds represented by Formula (I): 1
    Type: Application
    Filed: May 24, 2002
    Publication date: May 22, 2003
    Inventors: Chun Li, Mario Girard, Pierre Hamel, Sebastien Laliberte, Richard Friesen, Yves Girard, Daniel Guay
  • Patent number: 6562811
    Abstract: Pyridine compounds of general formula: wherein —R1 represents in which R11 is hydrogen, C1-6 alkyl, halogen, hydroxy, C1-12 alkoxy, nitro, amino, C1-6 alkylsulfonylamino, C1-6 alkoxycarbonyl, C1-6 alkylamino, di(C1-6 alkyl)amino, C1-6 alkanoylamino, phenyl C1-6 alkylamino, phenylsulfonylamino, or —O—(CH2)n—R111; R2 represents hydrogen or halogen; R3 represents hydrogen, —CR31R32R33, or —NR34R35; R4 is hydrogen, carbamoyl, CN, carboxyl, etc.; R5 is amino, C1-6 alkylamino, di C1-6 alkylamino, etc. or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity.
    Type: Grant
    Filed: September 18, 2001
    Date of Patent: May 13, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Toshiki Murata, Masaomi Umeda, Sachiko Sakakibara, Takashi Yoshino, Hiroki Sato, Tsutomu Masuda, Yuji Koriyama, Mitsuyuki Shimada, Takuya Shintani, Hiroshi Kadono, Timothy B. Lowinger, Karl B. Ziegelbauer, Kinji Fuchikami, Hiroshi Komura
  • Patent number: 6559145
    Abstract: The present invention provides a compound of formula I which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.
    Type: Grant
    Filed: June 22, 2001
    Date of Patent: May 6, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Fred L. Ciske, Michael J. Genin, Byung Hyun Lee, Mark E. Schnute, Valerie A. Vaillancourt
  • Publication number: 20030055071
    Abstract: Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described. These compounds are inhibitors of HIV integrase and inhibitors of HIV replication, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Application
    Filed: October 10, 2001
    Publication date: March 20, 2003
    Inventors: Neville J. Anthony, Robert P. Gomez, Steven D. Young, Melissa Egbertson, John S. Wai, Linghang Zhuang, Mark Embrey, LeKhanh Tran, Jeffrey Y. Melamed, H. Marie Langford, James P. Guare, Thorsten E. Fisher, Samson M. Jolly, Michelle S. Kuo, Debra S. Perlow, Jennifer J. Bennett, Timothy W. Funk
  • Publication number: 20030050321
    Abstract: 7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate and hydrates thereof, processes for their preparation, pharmaceutical compositions comprising them, and their use in antibacterial therapy.
    Type: Application
    Filed: August 20, 2002
    Publication date: March 13, 2003
    Applicant: LG Chemical Ltd.
    Inventors: Ae Ri Kim, Jin Hwa Lee, Ki Sook Park, Jong Ryoo Choi, Tae Hee Lee, Jay Hyok Chang, Do Hyun Nam, Hoon Choi
  • Patent number: 6531594
    Abstract: A process for producing 1H-3-aminopyrrolidine and derivatives thereof is disclosed.
    Type: Grant
    Filed: August 21, 2001
    Date of Patent: March 11, 2003
    Assignee: Mitsubishi Chemical Corporation
    Inventors: Michi Watanabe, Takeshi Nakato, Jun Takehara, Kazuaki Kanno, Shuji Ichikawa
  • Patent number: 6518283
    Abstract: Squaric acid Derivatives of formula (1) are described: wherein R1 is an integrin binding group; R2 is a hydrogen atom or a C1-6alkyl group; L1 is a covalent bond or a linker atom or group; n is zero or the integer 1; Alk1 is an optionally substituted aliphatic chain; R3 is a hydrogen atom or an optionally substituted heteroaliphatic, cycloaliphatic, heterocycloaliphatic, polycycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group: and the salts, solvates, hydrates and N-oxides thereof. The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immune of inflammatory disorders, or disorders involving the inappropriate growth or migration of cells.
    Type: Grant
    Filed: May 25, 2000
    Date of Patent: February 11, 2003
    Assignee: Celltech R&D Limited
    Inventors: Barry John Langham, Rikki Peter Alexander, John Clifford Head, Janeen Marsha Linsley, John Robert Porter, Sarah Catherine Archibald, Graham John Warrellow
  • Publication number: 20030018191
    Abstract: Process for the preparation of compounds of formula I 1
    Type: Application
    Filed: June 12, 2002
    Publication date: January 23, 2003
    Inventors: Michael Tinkl, Samuel Evans, Peter Nesvadba
  • Publication number: 20020188001
    Abstract: The present invention relates to novel crystalline forms of the integrin &agr;v&bgr;3 antagonist 3-{2-oxo-3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]imidazolidin-1-yl}-3(S)-(6-methoxy-pyridin-3-yl)-propionic acid.
    Type: Application
    Filed: June 11, 2002
    Publication date: December 12, 2002
    Inventors: Wei Xu, Yaling Wang
  • Patent number: 6492520
    Abstract: This invention relates to compounds of formula (I), wherein A, B, D, E, K, G, Z, R3 and R5 are defined as in the specification, and to the pharmaceutically acceptable salts of such compounds. Compounds (I) are corticotropin releasing factor (hormone) CRF (CRH) antagonists.
    Type: Grant
    Filed: May 24, 1999
    Date of Patent: December 10, 2002
    Assignee: Pfizer Inc
    Inventor: Yuhpyng L. Chen
  • Publication number: 20020183523
    Abstract: The present invention relates to an antimicrobial compound having high safety as well as potent antimicrobial activity on a broad range of microorganisms represented by the following formula: 1
    Type: Application
    Filed: March 28, 2002
    Publication date: December 5, 2002
    Applicant: DAIICHI PHARMACEUTICAL CO., LTD
    Inventors: Makoto Takemura, Youichi Kimura, Hisashi Takahashi, Yohhei Ishida
  • Publication number: 20020177604
    Abstract: The present invention provides a compound of Formula III 1
    Type: Application
    Filed: May 20, 2002
    Publication date: November 28, 2002
    Inventors: Valerie A. Vaillancourt, Atli Thorarensen
  • Publication number: 20020156280
    Abstract: The present invention encompasses structures of the Formula 1
    Type: Application
    Filed: April 2, 2002
    Publication date: October 24, 2002
    Applicant: Neurogen Corporation, Corporation of the State of Delaware
    Inventors: Pamela A. Albaugh, Robert W. DeSimone, Gang Liu
  • Patent number: 6469023
    Abstract: The present invention provides an antibacterial compound useful as medicines, animal drugs, fisheries drugs or antibacterial preservatives and to an antibacterial agent or preparation which contains the same, more particularly a compound which possesses high safety and excellent activity against a broad range of bacterial species including quinolone-resistant strains. A quinolone derivative of the following formula (I) which has a group derived from the heterocyclic spiro-compound at the 7-positioned R2 and the halogenocyclopropyl group at the N1-position, prefereably a compound of pure isomer, and an antibacterial agent containing the derivative compound.
    Type: Grant
    Filed: August 7, 1997
    Date of Patent: October 22, 2002
    Assignee: Daiichi Pharmaceutical Co., Ltd.
    Inventors: Makoto Takemura, Youichi Kimura, Hitoshi Ohki
  • Patent number: 6451811
    Abstract: The resent invention provides a compound of Formula III which is useful for the treatment or prevention of herpes viruses.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: September 17, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Valerie A. Vaillancourt, Atli Thorarensen
  • Publication number: 20020103220
    Abstract: The present invention provides compounds of formula I 1
    Type: Application
    Filed: June 5, 2001
    Publication date: August 1, 2002
    Inventor: Mark E. Schnute
  • Patent number: 6413958
    Abstract: Certain novel 4-hydroxy-1,8-naphthyridine-3-carboxyamides. The compounds are effective in the treatment or prevention of viral infections, particularly viral infections caused by herpes simplex viruses types 1 and 2, human herpes viruses types 6, 7 and 8, varicello zoster viruses, human cytomegaloviruses and Epstein-Barr viruses.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: July 2, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventor: Valerie A. Vaillancourt
  • Patent number: 6399604
    Abstract: The present invention encompasses structures of the Formula or the pharmaceutically acceptable non-toxic salts thereof wherein: X is hydrogen, halogen, (un)substituted alkyl, (un)substituted alkoxy or amino; and Y is (un)substituted alkyl, aryl, or heteroaryl, which compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors. These compounds are useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, and overdose with benzodiazepine drugs and for enhancement of alertness.
    Type: Grant
    Filed: August 8, 2000
    Date of Patent: June 4, 2002
    Assignee: Neurogen Corporation
    Inventors: Pamela A. Albaugh, Robert W. DeSimone, Gang Liu
  • Publication number: 20020061909
    Abstract: The present invention describes novel compounds of the formula:
    Type: Application
    Filed: September 7, 2001
    Publication date: May 23, 2002
    Inventors: Thomas D. Harris, Milind Rajopadhye
  • Publication number: 20020052502
    Abstract: The present invention relates to an antimicrobial compound having high safety as well as potent antimicrobial activity on a broad range of microorganisms represented by the following formula: 1
    Type: Application
    Filed: July 19, 2001
    Publication date: May 2, 2002
    Applicant: DAIICHI PHARMACEUTICAL CO., LTD.
    Inventors: Makoto Takemura, Youichi Kimura, Hisashi Takahashi, Yohhei Ishida
  • Publication number: 20020049328
    Abstract: Processes for producing a 7-isoindoline-quinolonecarboxylic acid derivative represented by the general formula [1] which is useful as an antibacterial agent, and an intermediate thereof: 1
    Type: Application
    Filed: September 25, 2001
    Publication date: April 25, 2002
    Applicant: TOYAMA CHEMICAL CO., LTD.
    Inventors: Minoru Yamada, Shoichi Hamamoto, Kazuya Hayashi, Kazuko Takaoka, Hiroko Matsukura, Minako Yotsuji, Kenji Yonezawa, Katsuji Ojima, Tamotsu Takamatsu, Kyoko Taya, Hirohiko Yamamoto, Taro Kiyoto, Hironori Kotsubo
  • Publication number: 20020049223
    Abstract: Compounds having formula (I) 1
    Type: Application
    Filed: May 7, 2001
    Publication date: April 25, 2002
    Inventors: Steven W. Elmore, Curt S. Cooper, Colleen C. Schultz, Douglas K. Hutchinson, Pamela L. Donner, Brian E. Green, David D. Anderson, Qinghua Xie, Jurgen Dinges, Linda M. Lynch, John K. Pratt
  • Patent number: 6358976
    Abstract: This invention relates to novel fused heterocycles which are useful as antagonists of the &agr;v&bgr;3 and related integrin receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.
    Type: Grant
    Filed: February 22, 2000
    Date of Patent: March 19, 2002
    Inventors: John Wityak, Aleksandra Ewa Tobin
  • Patent number: 6359137
    Abstract: Trovafloxacin acid salts are prepared via the hydrolysis of imine intermediates using mineral acid including, but not limited to, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, nitric acid, sulfuric acid, phosphoric acid, hydrochloric acid, hydrobromic acid, tartaric acid, citric acid, acetic acid, and maleic acid. Trovafloxacin acid salts are useful as antibiotic agents.
    Type: Grant
    Filed: August 26, 1999
    Date of Patent: March 19, 2002
    Assignee: Pfizer Inc.
    Inventors: Timothy Norris, Keith M. DeVries, Peter R. Rose
  • Publication number: 20020032216
    Abstract: 7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate and hydrates thereof, processes for their preparation, pharmaceutical compositions comprising them, and their use in antibacterial therapy.
    Type: Application
    Filed: August 6, 2001
    Publication date: March 14, 2002
    Applicant: LG Chemical Ltd.
    Inventors: Ae Ri Kim, Jin Hwa Lee, Ki Sook Park, Jong Ryoo Choi, Tae Hee Lee, Jay Hyok Chang, Do Hyun Nam, Hoon Choi
  • Publication number: 20020019413
    Abstract: The present invention provides a compound of Formula III 1
    Type: Application
    Filed: March 15, 2001
    Publication date: February 14, 2002
    Inventors: Valerie A. Vaillancourt, Atli Thorarensen
  • Publication number: 20020006935
    Abstract: A 1-aryl-1,8-naphthylidin-4-one derivative having the formula (I): 1
    Type: Application
    Filed: July 19, 2001
    Publication date: January 17, 2002
    Inventors: Tetsuo Shimamoto, Hidekazu Inoue, Yasuhiro Hayashi
  • Patent number: 6331548
    Abstract: A 1-cycloalkyl-1,8-naphthylidin-4-one derivative having the formula (I): wherein R1 indicates a substituted or unsubstituted cycloalkyl group or a substituted or unsubstituted heterocycloalkyl group, R2, R3, and R4 independently indicate a hydrogen atom, a substituted or unsubstituted lower alkyl group, or a halogen atom, X indicates a group NR5R6 or a group OR7, wherein R5 and R6 independently indicate a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group, and R7 indicates a hydrogen atom, a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted cycloalkyl group or a pharmaceutically acceptable salt or solvate thereof and a type IV phosphodiesterase inhibitor containing the same as an effective component.
    Type: Grant
    Filed: September 29, 1999
    Date of Patent: December 18, 2001
    Assignee: Suntory Limited
    Inventors: Tetsuo Shimamoto, Hidekazu Inoue, Yasuhiro Hayashi
  • Patent number: 6319920
    Abstract: This invention relates to muscarinic receptor antagonist compounds selected from the group of compounds represented by Formula I: wherein the substituents are as defined in the specification; and their pharmaceutically acceptable salts, individual isomers or a racemic or non-racemic mixture; pharmaceutical compositions containing them; and methods for their use as therapeutic agents.
    Type: Grant
    Filed: February 1, 1999
    Date of Patent: November 20, 2001
    Assignee: Syntex (U.S.A.) LLC
    Inventors: Joan Marie Caroon, Robin Douglas Clark, Michael Patrick Dillon, Ralph New Harris, III, Sharathchandra Surendra Hegde, Clara Jeou Jen Lin, Hans Maag, David Bruce Repke
  • Patent number: 6297248
    Abstract: A 1-aryl-1,8-naphthylidin-4-one derivative having the formula (I): wherein R1 indicates a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group, R2, R3, and R4 independently indicate a hydrogen atom, a substituted or unsubstituted lower alkyl group, or a halogen atom, X indicates a group NR5R6 or a group OR7, wherein R5 and R6 independently indicate a hydrogen a atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group, and R7 indicates a hydrogen atom, a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted cycloalkyl group or a salt or solvate thereof and a type IV phosphodiesterase inhibitor containing the same as an effective component.
    Type: Grant
    Filed: April 6, 1999
    Date of Patent: October 2, 2001
    Assignee: Suntory Limited
    Inventors: Tetsuo Shimamoto, Hidekazu Inoue, Yasuhiro Hayashi
  • Patent number: 6288081
    Abstract: The invention relates to the use of quinolone- and naphthyridonecarboxylic acid derivatives which are substituted in position 7 by a 1-aminomethyl-2-oxa-7-azabicyclo[3.3.0]oct-7-yl radical, and of their salts for the therapy of Helicobacter pylori infections and associated gastroduodenal disorders.
    Type: Grant
    Filed: August 6, 1999
    Date of Patent: September 11, 2001
    Assignee: Bayer Aktiengesellschaft
    Inventors: Uwe Petersen, Michael Matzke, Thomas Jaetsch, Thomas Schenke, Thomas Himmler, Stephan Bartel, Bernd Baasner, Hans-Otto Werling, Klaus Schaller, Harald Labischinski, Rainer Endermann